UCL Business, the technology transfer company of UCL, and venture capital firm F-Prime Capital Partners have launched Orchard Therapeutics, a biotechnology company specialising in gene therapies for life threatening rare childhood diseases.
Orchard Therapeutics has secured £21 million investment led by F-Prime to support the development of gene therapy treatments for a range of diseases.
As part of its launch, Orchard announced formal partnerships with UCL, Great Ormond Street Hospital for Children NHS Foundation Trust (GOSH), University of California Los Angeles (UCLA), The University of Manchester, Boston Children’s Hospital for the development of these transformative gene therapies.
Orchard’s lead programme is for the treatment of the rare and fatal disorder called severe combined immunodeficiency caused by adenosine deaminase deficiency (ADA-SCID), sometimes referred to as “bubble baby” syndrome in the press. Children with the disorder must be protected from any infections due to their highly fragile immune system.
In a first-in-man clinical study, global leaders in the field at UCL/GOSH and UCLA have shown significant immune reconstitution and 100% survival in 32 patients treated, as of March 2016.
Orchard’s financing has been led by F-Prime Capital, with support from UCLB and additional participation from the UCL Technology Fund.
Cengiz Tarhan, Managing Director of UCLB, said:
“We are very excited to see UCL’s breakthrough treatments move forward in a commercial environment in a way that will benefit patients globally. The formation of Orchard represents the culmination of decades of research at UCL and its partners and we are delighted to be able to work with F-Prime Capital to launch Orchard.”